University of Oklahoma Health Sciences Center, Stephenson Cancer Center Oklahoma City, Oklahoma, United States.
University of Oklahoma Health Sciences Center, Stephenson Cancer Center Oklahoma City, Oklahoma, United States.
Cancer Treat Res Commun. 2020;24:100199. doi: 10.1016/j.ctarc.2020.100199. Epub 2020 Jul 22.
Somatic or germline mutations in genes regulating DNA damage repair have been noted in around 20% of patients with advanced prostate cancer. Poly-ADP-ribose polymerase (PARP) inhibitors have shown encouraging efficacy in prostate cancer patients with DNA repair mutations. Two PARP inhibitors, olaparib, and rucaparib have recently received FDA approval for treatment of patients with advanced castration-resistant prostate cancer (CRPC), while several trials with other PARP inhibitors are ongoing. Here, we briefly summarize the current data supporting the efficacy of PARP inhibitors in advanced CRPC.
在约 20%的晚期前列腺癌患者中，已发现调节 DNA 损伤修复的基因存在体细胞或种系突变。聚 ADP-核糖聚合酶 (PARP) 抑制剂在具有 DNA 修复突变的前列腺癌患者中显示出令人鼓舞的疗效。两种 PARP 抑制剂奥拉帕利和芦卡帕利最近已获得 FDA 批准用于治疗晚期去势抵抗性前列腺癌 (CRPC) 患者，而其他 PARP 抑制剂的多项试验正在进行中。在这里，我们简要总结了支持 PARP 抑制剂在晚期 CRPC 中疗效的现有数据。
